The effect of Metformin combine with FOLFOX + Bevacizumab as the first-line therapy in metastatic colorectal cancer, a randomized, open, prospective clinical study (BeFoLMe study)
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2667687
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Study Group:Metformin 250mg per day combine with FOLFOX + Bevacizumab;Control Group:FOLFOX + Bevacizumab
Primary outcome(s): PFS, Progression-Free-Survival
Study Design: Randomized parallel controlled trial
创建时间：
2018-01-15
